Does the media favor ETON or OGN?

In the previous week, Eton Pharmaceuticals had 9 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 1 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.53 beat Eton Pharmaceuticals' score of 0.20 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Organon & Co. 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to EWTX or ETON?

In the previous week, Eton Pharmaceuticals had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 2 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.93 beat Eton Pharmaceuticals' score of 0.20 indicating that Edgewise Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ERAS or ETON?

In the previous week, Eton Pharmaceuticals had 5 more articles in the media than Erasca. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 5 mentions for Erasca. Erasca's average media sentiment score of 0.39 beat Eton Pharmaceuticals' score of 0.20 indicating that Erasca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Erasca 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, ETON or TLX?

Eton Pharmaceuticals has higher earnings, but lower revenue than Telix Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eton Pharmaceuticals $79.95M 10.43 -$4.60M -$0.07 N/A Telix Pharmaceuticals $803.79M 3.98 -$7.12M N/A N/A

Does the media favor ETON or TLX?

In the previous week, Eton Pharmaceuticals had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 3 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.64 beat Eton Pharmaceuticals' score of 0.20 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor DNLI or ETON?

In the previous week, Eton Pharmaceuticals had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.13 beat Eton Pharmaceuticals' score of 0.20 indicating that Denali Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eton Pharmaceuticals 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Eton Pharmaceuticals (ETON) Competitors

$30.45 0.00 (0.00%)

Closing price 05/29/2026 04:00 PM Eastern

Extended Trading

$31.25 +0.80 (+2.63%)

As of 05/29/2026 07:51 PM Eastern

Compare

ETON vs. OGN, EWTX, ERAS, TLX, and DNLI

Should you buy Eton Pharmaceuticals stock or one of its competitors? MarketBeat compares Eton Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eton Pharmaceuticals include Organon & Co. (OGN), Edgewise Therapeutics (EWTX), Erasca (ERAS), Telix Pharmaceuticals (TLX), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.

How does Eton Pharmaceuticals compare to Organon & Co.?

Eton Pharmaceuticals (NASDAQ:ETON) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, earnings, profitability, valuation and institutional ownership.

Organon & Co. has a net margin of 3.99% compared to Eton Pharmaceuticals' net margin of -1.70%. Organon & Co.'s return on equity of 99.95% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Organon & Co.	3.99%	99.95%	6.22%

Eton Pharmaceuticals currently has a consensus target price of $41.00, indicating a potential upside of 34.65%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 14.77%. Given Eton Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Eton Pharmaceuticals is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

In the previous week, Eton Pharmaceuticals had 9 more articles in the media than Organon & Co.. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 1 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 1.53 beat Eton Pharmaceuticals' score of 0.20 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Organon & Co.	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Organon & Co. has higher revenue and earnings than Eton Pharmaceuticals. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	10.43	-$4.60M	-$0.07	N/A
Organon & Co.	$6.22B	0.57	$187M	$0.93	14.38

Eton Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, suggesting that its share price is 55% more volatile than the broader market.

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. Comparatively, 77.4% of Organon & Co. shares are owned by institutional investors. 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Comparatively, 1.6% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Organon & Co. beats Eton Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Eton Pharmaceuticals (NASDAQ:ETON) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

Edgewise Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

In the previous week, Eton Pharmaceuticals had 8 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 2 mentions for Edgewise Therapeutics. Edgewise Therapeutics' average media sentiment score of 0.93 beat Eton Pharmaceuticals' score of 0.20 indicating that Edgewise Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

27.9% of Eton Pharmaceuticals shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Edgewise Therapeutics presently has a consensus price target of $39.67, indicating a potential upside of 16.12%. Eton Pharmaceuticals has a consensus price target of $41.00, indicating a potential upside of 34.65%. Given Eton Pharmaceuticals' higher possible upside, analysts plainly believe Eton Pharmaceuticals is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Eton Pharmaceuticals has higher revenue and earnings than Edgewise Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Eton Pharmaceuticals	$79.95M	10.43	-$4.60M	-$0.07	N/A

Edgewise Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Edgewise Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Summary

Eton Pharmaceuticals beats Edgewise Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Erasca?

Erasca (NASDAQ:ERAS) and Eton Pharmaceuticals (NASDAQ:ETON) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Erasca presently has a consensus target price of $18.75, indicating a potential upside of 46.03%. Eton Pharmaceuticals has a consensus target price of $41.00, indicating a potential upside of 34.65%. Given Erasca's stronger consensus rating and higher probable upside, equities research analysts clearly believe Erasca is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

67.8% of Erasca shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 14.2% of Erasca shares are held by insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Eton Pharmaceuticals had 5 more articles in the media than Erasca. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 5 mentions for Erasca. Erasca's average media sentiment score of 0.39 beat Eton Pharmaceuticals' score of 0.20 indicating that Erasca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Erasca	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Erasca has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Erasca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Eton Pharmaceuticals has higher revenue and earnings than Erasca. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Eton Pharmaceuticals	$79.95M	10.43	-$4.60M	-$0.07	N/A

Erasca has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the broader market.

Summary

Eton Pharmaceuticals beats Erasca on 8 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Telix Pharmaceuticals?

Eton Pharmaceuticals (NASDAQ:ETON) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Telix Pharmaceuticals has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Telix Pharmaceuticals' return on equity of 0.00% beat Eton Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%
Telix Pharmaceuticals	N/A	N/A	N/A

27.9% of Eton Pharmaceuticals shares are held by institutional investors. 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Eton Pharmaceuticals presently has a consensus target price of $41.00, suggesting a potential upside of 34.65%. Telix Pharmaceuticals has a consensus target price of $21.13, suggesting a potential upside of 124.02%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Telix Pharmaceuticals is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

In the previous week, Eton Pharmaceuticals had 7 more articles in the media than Telix Pharmaceuticals. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 3 mentions for Telix Pharmaceuticals. Telix Pharmaceuticals' average media sentiment score of 0.64 beat Eton Pharmaceuticals' score of 0.20 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Eton Pharmaceuticals has higher earnings, but lower revenue than Telix Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eton Pharmaceuticals	$79.95M	10.43	-$4.60M	-$0.07	N/A
Telix Pharmaceuticals	$803.79M	3.98	-$7.12M	N/A	N/A

Eton Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.1, indicating that its share price is 110% less volatile than the broader market.

Summary

Telix Pharmaceuticals beats Eton Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

How does Eton Pharmaceuticals compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Eton Pharmaceuticals (NASDAQ:ETON) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 27.9% of Eton Pharmaceuticals shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Comparatively, 16.5% of Eton Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Eton Pharmaceuticals had 7 more articles in the media than Denali Therapeutics. MarketBeat recorded 10 mentions for Eton Pharmaceuticals and 3 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 1.13 beat Eton Pharmaceuticals' score of 0.20 indicating that Denali Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eton Pharmaceuticals	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eton Pharmaceuticals has lower revenue, but higher earnings than Denali Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.10	-$512.54M	-$2.88	N/A
Eton Pharmaceuticals	$79.95M	10.43	-$4.60M	-$0.07	N/A

Denali Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -1.70%. Eton Pharmaceuticals' return on equity of -5.68% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Eton Pharmaceuticals	-1.70%	-5.68%	-1.49%

Denali Therapeutics currently has a consensus price target of $34.25, suggesting a potential upside of 62.79%. Eton Pharmaceuticals has a consensus price target of $41.00, suggesting a potential upside of 34.65%. Given Denali Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Denali Therapeutics is more favorable than Eton Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
Eton Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Denali Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Eton Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Summary

Denali Therapeutics beats Eton Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

Get Eton Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ETON vs. The Competition

Export

Metric	Eton Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$834.03M	$3.40B	$6.41B	$12.57B
Dividend Yield	N/A	2.29%	2.68%	5.31%
P/E Ratio	-434.94	18.88	21.61	26.27
Price / Sales	10.43	334.85	561.77	114.93
Price / Cash	N/A	54.19	27.44	37.60
Price / Book	31.07	6.93	10.04	6.86
Net Income	-$4.60M	$24.20M	$3.56B	$337.26M
7 Day Performance	-6.57%	4.11%	2.82%	3.58%
1 Month Performance	N/A	N/A	N/A	-0.79%
1 Year Performance	61.11%	66.00%	37.62%	39.67%

Eton Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ETON Eton Pharmaceuticals	4.4345 of 5 stars	$30.45 flat	$41.00 +34.6%	+61.1%	$834.03M	$79.95M	N/A	20
OGN Organon & Co.	2.8491 of 5 stars	$13.44 +0.0%	$11.40 -15.1%	+45.4%	$3.53B	$6.22B	14.45	10,000	Positive News
EWTX Edgewise Therapeutics	1.6265 of 5 stars	$32.70 flat	$39.67 +21.3%	+140.6%	$3.52B	N/A	N/A	60	Gap Down
ERAS Erasca	3.0136 of 5 stars	$11.24 flat	$18.75 +66.8%	+807.4%	$3.50B	N/A	N/A	120	Gap Down
TLX Telix Pharmaceuticals	4.5428 of 5 stars	$9.47 flat	$21.13 +123.1%	-43.7%	$3.21B	$803.79M	N/A	1,184	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ETON) was last updated on 6/1/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eton Pharmaceuticals (ETON) Competitors

ETON vs. OGN, EWTX, ERAS, TLX, and DNLI

How does Eton Pharmaceuticals compare to Organon & Co.?

Summary

How does Eton Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does Eton Pharmaceuticals compare to Erasca?

Summary

How does Eton Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Eton Pharmaceuticals compare to Denali Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eton Pharmaceuticals (ETON) Competitors

ETON vs. OGN, EWTX, ERAS, TLX, and DNLI

How does Eton Pharmaceuticals compare to Organon & Co.?

Is ETON or OGN more profitable?

Do analysts rate ETON or OGN?

Does the media favor ETON or OGN?

Which has preferable valuation and earnings, ETON or OGN?

Which has more risk & volatility, ETON or OGN?

Do insiders and institutionals believe in ETON or OGN?

Summary

How does Eton Pharmaceuticals compare to Edgewise Therapeutics?

Which has more volatility & risk, EWTX or ETON?

Does the media refer more to EWTX or ETON?

Do institutionals & insiders believe in EWTX or ETON?

Do analysts rate EWTX or ETON?

Which has preferable valuation and earnings, EWTX or ETON?

Is EWTX or ETON more profitable?

Summary

How does Eton Pharmaceuticals compare to Erasca?

Do analysts prefer ERAS or ETON?

Do institutionals and insiders believe in ERAS or ETON?

Does the media prefer ERAS or ETON?

Is ERAS or ETON more profitable?

Which has better earnings and valuation, ERAS or ETON?

Which has more risk & volatility, ERAS or ETON?

Summary

How does Eton Pharmaceuticals compare to Telix Pharmaceuticals?

Is ETON or TLX more profitable?

Do institutionals and insiders believe in ETON or TLX?

Do analysts rate ETON or TLX?

Does the media favor ETON or TLX?

Which has better earnings & valuation, ETON or TLX?

Which has more risk & volatility, ETON or TLX?

Summary

How does Eton Pharmaceuticals compare to Denali Therapeutics?

Do institutionals & insiders believe in DNLI or ETON?

Does the media favor DNLI or ETON?

Which has higher earnings and valuation, DNLI or ETON?

Is DNLI or ETON more profitable?

Do analysts rate DNLI or ETON?

Which has more volatility & risk, DNLI or ETON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ETON vs. The Competition

Eton Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools